Literature DB >> 19401543

Physical activity, weight control, and breast cancer risk and survival: clinical trial rationale and design considerations.

Rachel Ballard-Barbash1, Sally Hunsberger, Marianne H Alciati, Steven N Blair, Pamela J Goodwin, Anne McTiernan, Rena Wing, Arthur Schatzkin.   

Abstract

Substantial observational epidemiological evidence exists that physical activity and weight control are associated with decreased risk of postmenopausal breast cancer. Uncertainty remains regarding several aspects of these associations, including the effect of possible confounding factors on these associations. We present the rationale and design for two randomized controlled trials that can help resolve this uncertainty. In a 5-year prevention trial conducted among women at high risk of breast cancer, the primary endpoint would be breast cancer incidence. For a comparable survivorship trial, the primary endpoint would be the disease-free interval and secondary endpoints would be breast cancer recurrence-free interval, second primary breast cancer, and total invasive plus in situ breast cancer. A set of inclusion and exclusion criteria is proposed for both trials. Intervention goals are the same for both trials. Goals for the weight control intervention would be, for women whose body mass index (BMI) is greater than 25 kg/m(2), to lose 10% of body weight and, for women whose BMI is less than or equal to 25 kg/m(2), to avoid weight gain. The goal for the physical activity intervention would be to achieve and maintain regular participation in a moderate-intensity physical activity program for a total of 150-225 minutes over at least 5 days per week. Sample size calculations are based on alternative assumptions about hazard ratio, adherence, follow-up duration, and power and are presented for the primary prevention and survivorship trials. Although both studies could enhance our understanding of breast cancer etiology and benefit public health, practical considerations, including smaller sample size, ease of recruitment, and reduced likelihood of early termination, favor the survivorship trial at this time.

Entities:  

Mesh:

Year:  2009        PMID: 19401543      PMCID: PMC2677576          DOI: 10.1093/jnci/djp068

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  71 in total

Review 1.  The role of energy density in the overconsumption of fat.

Authors:  B J Rolls
Journal:  J Nutr       Date:  2000-02       Impact factor: 4.798

2.  Methods of ensuring high follow-up rates: lessons from a longitudinal study of dual diagnosed participants.

Authors:  B J BootsMiller; K M Ribisl; C T Mowbray; W S Davidson; M A Walton; S E Herman
Journal:  Subst Use Misuse       Date:  1998-11       Impact factor: 2.164

3.  Approached to monitoring the results of long-term disease prevention trials: examples from the Women's Health Initiative.

Authors:  L Freedman; G Anderson; V Kipnis; R Prentice; C Y Wang; J Rossouw; J Wittes; D DeMets
Journal:  Control Clin Trials       Date:  1996-12

4.  A prospective study of body mass index, weight change, and risk of stroke in women.

Authors:  K M Rexrode; C H Hennekens; W C Willett; G A Colditz; M J Stampfer; J W Rich-Edwards; F E Speizer; J E Manson
Journal:  JAMA       Date:  1997-05-21       Impact factor: 56.272

5.  Changes in body fat and weight after a breast cancer diagnosis: influence of demographic, prognostic, and lifestyle factors.

Authors:  Melinda L Irwin; Anne McTiernan; Richard N Baumgartner; Kathy B Baumgartner; Leslie Bernstein; Frank D Gilliland; Rachel Ballard-Barbash
Journal:  J Clin Oncol       Date:  2005-02-01       Impact factor: 44.544

6.  Body size, physical activity, and breast cancer hormone receptor status: results from two case-control studies.

Authors:  S M Enger; R K Ross; A Paganini-Hill; C L Carpenter; L Bernstein
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2000-07       Impact factor: 4.254

7.  Dual effects of weight and weight gain on breast cancer risk.

Authors:  Z Huang; S E Hankinson; G A Colditz; M J Stampfer; D J Hunter; J E Manson; C H Hennekens; B Rosner; F E Speizer; W C Willett
Journal:  JAMA       Date:  1997-11-05       Impact factor: 56.272

8.  Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

Authors:  A Howell; J Cuzick; M Baum; A Buzdar; M Dowsett; J F Forbes; G Hoctin-Boes; J Houghton; G Y Locker; J S Tobias
Journal:  Lancet       Date:  2005 Jan 1-7       Impact factor: 79.321

9.  Physical activity and risk of stroke in women.

Authors:  F B Hu; M J Stampfer; G A Colditz; A Ascherio; K M Rexrode; W C Willett; J E Manson
Journal:  JAMA       Date:  2000-06-14       Impact factor: 56.272

10.  Comparison of lifestyle and structured interventions to increase physical activity and cardiorespiratory fitness: a randomized trial.

Authors:  A L Dunn; B H Marcus; J B Kampert; M E Garcia; H W Kohl; S N Blair
Journal:  JAMA       Date:  1999-01-27       Impact factor: 56.272

View more
  56 in total

Review 1.  Exercise therapy in the management of solid tumors.

Authors:  Lee W Jones; Jeffrey Peppercom; Jessica M Scott; Claudio Battaglini
Journal:  Curr Treat Options Oncol       Date:  2010-06

Review 2.  Integrative Therapies and Cardiovascular Disease in the Breast Cancer Population: A Review, Part 2.

Authors:  Khara Lucius; Kristen Trukova
Journal:  Integr Med (Encinitas)       Date:  2015-10

Review 3.  Impact of obesity on cancer survivorship and the potential relevance of race and ethnicity.

Authors:  Kathryn H Schmitz; Marian L Neuhouser; Tanya Agurs-Collins; Krista A Zanetti; Lisa Cadmus-Bertram; Lorraine T Dean; Bettina F Drake
Journal:  J Natl Cancer Inst       Date:  2013-08-29       Impact factor: 13.506

4.  Exercise and dietary advice intervention for survivors of triple-negative breast cancer: effects on body fat, physical function, quality of life, and adipokine profile.

Authors:  Anne K Swisher; Jame Abraham; Daniel Bonner; Diana Gilleland; Gerald Hobbs; Sobha Kurian; Mary Anne Yanosik; Linda Vona-Davis
Journal:  Support Care Cancer       Date:  2015-03-01       Impact factor: 3.603

5.  Wheel running-induced changes in plasma biomarkers and carcinogenic response in the 1-methyl-1-nitrosourea-induced rat model for breast cancer.

Authors:  Henry J Thompson; Pamela Wolfe; Anne McTiernan; Weiqin Jiang; Zongjian Zhu
Journal:  Cancer Prev Res (Phila)       Date:  2010-09-28

6.  Preventing weight gain in African American breast cancer survivors using smart scales and activity trackers: a randomized controlled pilot study.

Authors:  Carmina G Valle; Allison M Deal; Deborah F Tate
Journal:  J Cancer Surviv       Date:  2016-09-08       Impact factor: 4.442

7.  Wheel running, skeletal muscle aerobic capacity and 1-methyl-1-nitrosourea induced mammary carcinogenesis in the rat.

Authors:  Phillip B Mann; Weiqin Jiang; Zongjian Zhu; Pamela Wolfe; Anne McTiernan; Henry J Thompson
Journal:  Carcinogenesis       Date:  2010-03-18       Impact factor: 4.944

8.  Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831.

Authors:  Jennifer A Crozier; Alvaro Moreno-Aspitia; Karla V Ballman; Amylou C Dueck; Barbara A Pockaj; Edith A Perez
Journal:  Cancer       Date:  2013-04-12       Impact factor: 6.860

Review 9.  Breast cancer epidemic in the early twenty-first century: evaluation of risk factors, cumulative questionnaires and recommendations for preventive measures.

Authors:  Olga Golubnitschaja; Manuel Debald; Kristina Yeghiazaryan; Walther Kuhn; Martin Pešta; Vincenzo Costigliola; Godfrey Grech
Journal:  Tumour Biol       Date:  2016-07-22

10.  Intensity and timing of physical activity in relation to postmenopausal breast cancer risk: the prospective NIH-AARP diet and health study.

Authors:  Tricia M Peters; Steven C Moore; Gretchen L Gierach; Nicholas J Wareham; Ulf Ekelund; Albert R Hollenbeck; Arthur Schatzkin; Michael F Leitzmann
Journal:  BMC Cancer       Date:  2009-10-01       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.